Lowest-Rated StocksLowest-RatedNASDAQ:RXST RxSight (RXST) Stock Price, News & Analysis $5.37 +0.15 (+2.87%) As of 11:17 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About RxSight Stock (NASDAQ:RXST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RxSight alerts:Sign Up Key Stats Today's Range$5.22▼$5.4750-Day Range$4.59▼$7.6152-Week Range$4.48▼$13.96Volume158,724 shsAverage Volume877,782 shsMarket Capitalization$222.30 millionP/E RatioN/ADividend YieldN/APrice Target$9.44Consensus RatingReduce Company Overview RxSight, Inc. is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction. Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions. The company obtained CE marking in Europe for its LAL technology and later secured U.S. Food and Drug Administration approval for its second‐generation device in October 2020. Since then, RxSight has partnered with leading ophthalmology centers to integrate the LAL system into clinical practice, building a network of implantation sites throughout North America and preparing for broader global expansion under existing regulatory frameworks. In addition to its core LAL offering, RxSight continues to invest in research and development aimed at enhancing its lens portfolio and refining adjustment protocols. The company collaborates with ophthalmic surgeons and research institutions to advance surgical workflows and patient education initiatives. Under the leadership of President and Chief Executive Officer Steve McKnight, RxSight is committed to driving innovation in presbyopia correction and setting new standards for patient-centric eye care solutions.AI Generated. May Contain Errors. Read More RxSight Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreRXST MarketRank™: RxSight scored higher than 51% of companies evaluated by MarketBeat, and ranked 442nd out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingReduce Consensus RatingRxSight has received a consensus rating of Reduce. The company's average rating score is 1.93, and is based on no strong buy ratings, 2 buy ratings, 10 hold ratings, and 3 sell ratings.Upside PotentialRxSight has a consensus price target of $9.44, representing about 78.1% upside from its current price of $5.30.Amount of Analyst CoverageRxSight has only been the subject of 3 research reports in the past 90 days.Read more about RxSight's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for RxSight are expected to grow in the coming year, from ($1.41) to ($1.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of RxSight is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of RxSight is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRxSight has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about RxSight's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.20% of the float of RxSight has been sold short.Short Interest Ratio / Days to CoverRxSight has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in RxSight has recently decreased by 14.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRxSight does not currently pay a dividend.Dividend GrowthRxSight does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for RxSight this week, compared to 8 articles on an average week. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, RxSight insiders have not sold or bought any company stock.Percentage Held by Insiders10.05% of the stock of RxSight is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.78% of the stock of RxSight is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about RxSight's insider trading history. Receive RXST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RxSight and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RXST Stock News HeadlinesRxSight (NASDAQ:RXST) Trading 4.9% Higher - Still a Buy?June 23 at 2:21 AM | americanbankingnews.comRxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology ForumMay 19, 2026 | globenewswire.comSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.June 24 at 1:00 AM | Behind the Markets (Ad)RxSight, Inc. (RXST) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comRxSight (RXST) Q1 2026 Earnings TranscriptMay 12, 2026 | finance.yahoo.comRxSight, Inc. (RXST) Q1 2026 Earnings Call TranscriptMay 9, 2026 | seekingalpha.comRxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales OutlookMay 6, 2026 | globenewswire.comHow The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target ResetsMay 4, 2026 | finance.yahoo.comSee More Headlines RXST Stock Analysis - Frequently Asked Questions How have RXST shares performed this year? RxSight's stock was trading at $10.42 at the start of the year. Since then, RXST stock has decreased by 49.1% and is now trading at $5.3040. How were RxSight's earnings last quarter? RxSight, Inc. (NASDAQ:RXST) posted its earnings results on Wednesday, November, 5th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.15. The business's revenue was down 31.4% compared to the same quarter last year. Read the conference call transcript. When did RxSight IPO? RxSight (RXST) raised $125 million in an initial public offering (IPO) on Wednesday, July 28th 2021. The company issued 7,350,000 shares at $16.00-$18.00 per share. Who are RxSight's major shareholders? RxSight's top institutional shareholders include Bank of America Corp DE (2.92%), Healthcare of Ontario Pension Plan Trust Fund (2.73%), Walleye Capital LLC (0.76%) and Y Intercept Hong Kong Ltd (0.48%). Insiders that own company stock include Ronald M Md Kurtz, Eric Weinberg, Ilya Goldshleger, Ilya Goldshleger, Julie Andrews, Bakker Juliet Tammenoms, Robert Keith Warner, Tamara Fountain, William J Phd Link, Shelley B Thunen, Shweta Maniar and Jesse Anderson Corley. View institutional ownership trends. How do I buy shares of RxSight? Shares of RXST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of RxSight own? Based on aggregate information from My MarketBeat watchlists, some other companies that RxSight investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), e.l.f. Beauty (ELF), ServiceNow (NOW), Arista Networks (ANET) and Disc Medicine (IRON). Company Calendar Last Earnings11/05/2025Today6/24/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 RXST's financial health is in the Red zone, according to TradeSmith. RXST has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:RXST CIK1111485 Webwww.rxsight.com Phone949-521-7830FaxN/AEmployees220Year Founded1997Price Target and Rating Average Price Target for RxSight$9.44 High Price Target$11.00 Low Price Target$9.00 Potential Upside/Downside+76.7%Consensus RatingReduce Rating Score (0-4)1.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($1.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.94 million Net Margins-36.58% Pretax Margin-36.54% Return on Equity-17.01% Return on Assets-15.12% Debt Debt-to-Equity RatioN/A Current Ratio10.20 Quick Ratio8.93 Sales & Book Value Annual Sales$127.48 million Price / Sales1.74 Cash FlowN/A Price / Cash FlowN/A Book Value$6.70 per share Price / Book0.80Miscellaneous Outstanding Shares41,397,000Free Float37,237,000Market Cap$221.27 million OptionableOptionable Beta1.14 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:RXST) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersFour winners over 400%. Here's #5CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...Golden Portfolio | Sponsored25-Cent Gold Explorer Set to Drill Top Canadian Mineral BeltWith gold racing toward US$5,000 an ounce, one sub-$0.25 explorer is launching a fully funded drill campaign o...Resource Stock Digest | SponsoredMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredBlackRock's CEO is calling this "the next major evolution"Larry Fink, CEO of BlackRock - the world's largest asset manager with $10 trillion under management - is calli...Awesomely, LLC | SponsoredBig Oil knew about this for 50 yearsIn the 1970s, Chevron, Unocal, and Texaco all drilled the same energy source - and walked away to protect oil ...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredViral “AI Black Paper”A former CIA advisor is warning that an AI bubble collapse could trigger an 80 percent drop in the Dow as soon...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
